Efficacy of neuroprotective treatment including pyrimidine nucleotides in secondary uveitic glaucoma
Journal Title: Офтальмологический журнал - Year 2018, Vol 0, Issue 2
Abstract
Background: Secondary glaucoma is found in 18% to 38% of patients with uveitis, and is one of the most severe uveitic complications. The glaucomatous process is characterized by the progressive optic nerve neuropathy. The lack of efficacy of conventional neuroprotective approaches urged us to search for novel medications capable of stabilizing glaucoma. Purpose: To investigate the efficacy of neuroprotective treatment with pyrimidine nucleotides for secondary uveitic glaucoma. Materials and Methods: Patients with secondary uveitic glaucoma were divided into the study group (23 patients; 23 eyes) and the control group (21 patients; 21 eyes). The multicomponent neuroprotective treatment of the study group (but not of the control group) included a direct neuroprotector, Nucleo CMP Forte® drug containing two pyrimidine nucleotides, cytidine 5'-monophosphate and uridine 5'- triphosphate. The group received 2 ml of the drug intramuscularly daily for 10 days, and, thereafter, 2 capsules orally twice daily for 20 days. Each patient underwent visual acuity measurement and perimetry. In addition, phosphene threshold current (PTC) and critical frequency of phosphene (CFP) were determined. Results: Although no improvements in functional characteristics of the visual system were observed in the control group, the use of the pyrimidine nucleotide-containing drug as a component of therapy for uveitic glaucoma contributed to a 39% improvement in visual acuity, 17% increase in total visual field, 22% decrease in PTC, and 23% increase in CFP compared with baseline. Our long-term findings evidence that glaucoma was stabilized with neuroprotective therapy including, in particular, Nucleo CMP Forte, with generally maintained peripapillary RNFL thickness. Conclusion: The use of the pyrimidine nucleotide-containing drug as a component of therapy for uveitic glaucoma promoted an improvement in visual function and contributed to stabilization of glaucoma over 6-8 months
Authors and Affiliations
V. Savko Snr
Keywords
Related Articles
- EP ID EP422113
- DOI 10.31288/oftalmolzh/2018/2/2933
- Views 103
- Downloads 0
Influence of local and systemic factors of type 2 diabetes mellitus on the functional status of platelets in patients with diabetic retinopathy and maculopathy
Background: To date, there is no information on relationships of systemic (activation of the sympathoadrenal and renin- angiotensin systems, SAS and RAS, respectively) and local (inflammation and remodeling of the retina...
Cranial nerve III and/or VI function abnormalities associated with active herpesvirus infection: Clinical experience and literature review
Background: The field of oculomotor abnormalities (OMA) is of clinical and social importance. There is a group of OMA of unknown etiology. Purpose: To investigate the presence of DNA of herpesviruses venous blood of pat...
The contribution of Acad. N.A. Puchkovskaia to advances in ocular trauma management
The paper has sought to summarize the contribution of Acad. N.A. Puchkovskaia to advances in the understanding, treatment and care of people with eye trauma. The unified emergency eye trauma care system was established i...
A Case Report of Takayasu’s Arteritis
Background: Takayasu’s arteritis is a non-specific autoimmune disease affecting large-size blood vessels, with a predilection for the aorta and its major branches. The most characteristic symptoms include absence or decr...
Comparison study of results of vitrectomy and vitrectomy with scleral buckling for the treatment of patients with rhegmatogenous retinal detachment at high risk proliferative vitreoretinopathy
The aim of our study was to analyze the effectiveness of vitrectomy and vitrectomy with scleral buckling in patients with a high risk of proliferative vitreoretinopathy. Material and Methods: Of the 367 patients (394 ey...